Prospective Grant of an Exclusive Patent License: Development and Commercialization of Mifepristone and Analogues To Treat Hypercortisolism-Related Insulin Resistance Disorders
Updated under an hour ago ()
The National Institute of Diabetes and Digestive and Kidney Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the invention embodied in the patents and patent applications listed in the Supplementary Information section of this notice to Nulyn Science ("Nulyn"), a company located in Paris, France.
- Tags
- information blocking, Notice, Health and Human Services Department, National Institutes of Health, health IT
- Related exam domains
- None matched
- Source record id
- 2026-17991
- First seen by InfoSec Signals
- Sep 23, 2026
Source: Federal Register API, Office of the Federal Register, National Archives and Records Administration about this source more from it
Exam domain labels come from a keyword heuristic and are study hints, not an official mapping. The summary is the publisher's own text, shortened; the linked record is authoritative.